Investor Presentaiton

Key Deals & Rationale Rationale SUN PHARMA Enhances specialty pipeline. Local manufacturing capability to enhance presence in Russian market Strengthening the distribution of Tildrakizumab in Europe Year Deals Country Acquired global rights for OTX-101 & 2016 Global Odomzo 2016 Acquired Biosintez Russia 2016 Licensing agreement with Almirall for Tildrakizumab for Psoriasis Europe 2016 Acquired 14 brands from Novartis Japan Entry into Japan Distribution agreement with 2016 India AstraZeneca 2015 Acquired InSite Vision Inc. US 2015 Acquisition of GSK's Opiates Business Global Markets 2015 Distribution agreement with AstraZeneca India Distribution services agreement in India for brand "Oxra" & "Oxramet"Ⓡ (brands of dipagliflozin, used for diabetes treatment) Strengthens branded ophthalmic portfolio in U.S. Vertical Integration for controlled substances business Distribution services agreement in India for brand "Axcer" ® (brand of ticagrelor, used for the treatment of acute coronary syndrome) Strengthen position as the 5th largest Global Specialty Generic Pharma Company, No.1 Pharma Company in India & Strong positioning in Emerging Markets Strengthening the specialty product pipeline 2015 Sun Pharma - Ranbaxy Merger Global Markets 2014 In-licensing agreement with Merck for Tildrakizumab a biologic for psoriasis Global Markets 2014 Acquired Pharmalucence US Sterile injectable capacity in the US 2013 Acquired URL's generic business US Adds 107 products to US portfolio 2012 Acquired DUSA Pharma, Inc. US Acquired Taro Pharmaceutical 2010 Israel Industries Ltd. 1997 Acquired Caraco Detroit, US Access to branded derma product Dermatology & Topical Product Manufacturing Plant at Israel & Canada Entry into US Market © Sun Pharmaceutical Industries Limited. All Rights Reserved. 14

View entire presentation